Eliquis (apixaban), a direct inhibitor of factor Xa (FXa), was approved by the European Commission on May 18, 2011 for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
基本文件流程错误SQL调试用户
请求信息 : 2025-04-02 13:41:36 HTTP/1.1 GET : https://senovatech.com/anti_bacteria/206.html